Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections

Updates in Management of Complicated Urinary Tract Infections

(2018) Adrienne H. Ma et al.   AMERICAN JOURNAL OF THERAPEUTICS

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

(2018) Jonathan C. Cho et al.   ANNALS OF PHARMACOTHERAPY

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

(2018) Christopher M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration

(2018) James M. Kidd et al.   CLINICAL THERAPEUTICS

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

(2018) Michael A. Pfaller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

(2018) Keith S. Kaye et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study

(2018) Laura Vallejo-Torres et al.   BMJ Open

Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT)

(2017) Keith S Kaye et al.   Open Forum Infectious Diseases

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?

(2016) Federico Perez et al.   EXPERT OPINION ON PHARMACOTHERAPY

An update on the management of urinary tract infections in the era of antimicrobial resistance

(2016) Mazen S Bader et al.   POSTGRADUATE MEDICINE

The global epidemiology of carbapenemase-producing Enterobacteriaceae

(2016) David van Duin et al.   Virulence

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

(2015) Romney M. Humphries et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

(2015) Scott J. Hecker et al.   JOURNAL OF MEDICINAL CHEMISTRY

Urinary tract infections: epidemiology, mechanisms of infection and treatment options

(2015) Ana L. Flores-Mireles et al.   NATURE REVIEWS MICROBIOLOGY

Carbapenems: Past, Present, and Future

(2011) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY